Luoxin Pharmaceuticals Group Stock Co Ltd (002793) - Total Assets
Based on the latest financial reports, Luoxin Pharmaceuticals Group Stock Co Ltd (002793) holds total assets worth CN¥3.57 Billion CNY (≈ $522.28 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 002793 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Luoxin Pharmaceuticals Group Stock Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Luoxin Pharmaceuticals Group Stock Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore 002793 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Luoxin Pharmaceuticals Group Stock Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Luoxin Pharmaceuticals Group Stock Co Ltd's total assets of CN¥3.57 Billion consist of 51.8% current assets and 48.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.8% |
| Accounts Receivable | CN¥429.32 Million | 11.5% |
| Inventory | CN¥323.62 Million | 8.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥599.46 Million | 16.1% |
| Goodwill | CN¥1.95 Million | 0.1% |
Asset Composition Trend (2011–2025)
This chart illustrates how Luoxin Pharmaceuticals Group Stock Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002793 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Luoxin Pharmaceuticals Group Stock Co Ltd's current assets represent 51.8% of total assets in 2025, a decrease from 75.2% in 2011.
- Cash Position: Cash and equivalents constituted 14.8% of total assets in 2025, down from 24.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 2.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 16.1% of total assets.
Luoxin Pharmaceuticals Group Stock Co Ltd Competitors by Total Assets
Key competitors of Luoxin Pharmaceuticals Group Stock Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Luoxin Pharmaceuticals Group Stock Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.76 | 0.73 | 1.84 |
| Quick Ratio | 0.61 | 0.52 | 1.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-552.24 Million | CN¥-598.20 Million | CN¥2.63 Billion |
Luoxin Pharmaceuticals Group Stock Co Ltd - Advanced Valuation Insights
This section examines the relationship between Luoxin Pharmaceuticals Group Stock Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.42 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -14.1% |
| Total Assets | CN¥3.73 Billion |
| Market Capitalization | $636.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Luoxin Pharmaceuticals Group Stock Co Ltd's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Luoxin Pharmaceuticals Group Stock Co Ltd's assets decreased by 14.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2025)
The table below shows the annual total assets of Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.73 Billion ≈ $545.13 Million |
-14.08% |
| 2024-12-31 | CN¥4.34 Billion ≈ $634.49 Million |
-15.27% |
| 2023-12-31 | CN¥5.12 Billion ≈ $748.84 Million |
-36.88% |
| 2022-12-31 | CN¥8.11 Billion ≈ $1.19 Billion |
-14.63% |
| 2021-12-31 | CN¥9.50 Billion ≈ $1.39 Billion |
+22.99% |
| 2020-12-31 | CN¥7.72 Billion ≈ $1.13 Billion |
+3.50% |
| 2019-12-31 | CN¥7.46 Billion ≈ $1.09 Billion |
+432.24% |
| 2018-12-31 | CN¥1.40 Billion ≈ $205.12 Million |
+55.93% |
| 2017-12-31 | CN¥898.93 Million ≈ $131.54 Million |
+10.58% |
| 2016-12-31 | CN¥812.89 Million ≈ $118.95 Million |
+47.91% |
| 2015-12-31 | CN¥549.60 Million ≈ $80.42 Million |
+22.72% |
| 2014-12-31 | CN¥447.86 Million ≈ $65.54 Million |
+23.28% |
| 2013-12-31 | CN¥363.30 Million ≈ $53.16 Million |
-2.42% |
| 2012-12-31 | CN¥372.31 Million ≈ $54.48 Million |
+36.91% |
| 2011-12-31 | CN¥271.94 Million ≈ $39.79 Million |
-- |
About Luoxin Pharmaceuticals Group Stock Co Ltd
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. … Read more